Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 5 | $1.10 | $1.10 | $1.10 |
Q2 2024 | 5 | $1.13 | $1.13 | $1.13 |
Q3 2024 | 5 | $1.49 | $1.52 | $1.51 |
Q4 2024 | 12 | $1.38 | $1.99 | $1.63 |
Q1 2025 | 5 | $1.22 | $1.71 | $1.46 |
Q2 2025 | 4 | $1.55 | $1.68 | $1.60 |
Q3 2025 | 4 | $1.64 | $1.78 | $1.70 |
Q4 2025 | 4 | $1.91 | $2.08 | $1.98 |
Q1 2026 | 3 | $2.02 | $2.19 | $2.09 |
Q2 2026 | 3 | $2.31 | $2.51 | $2.39 |
Q3 2026 | 3 | $2.45 | $2.66 | $2.54 |
Q4 2026 | 3 | $2.64 | $2.87 | $2.74 |
Neurocrine Biosciences, Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $1.24 earnings per share for the quarter, missing analysts' consensus estimates of $1.51 by $0.27. The company had revenue of 622.10 M for the quarter and had revenue of 1.89 B for the year. Neurocrine Biosciences, Inc. has generated $3 earnings per share over the last year ($2.47 diluted earnings per share) and currently has a price-to-earnings ratio of 35.48. Neurocrine Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/30/2024 | Q3 2024 | $1.51 | $1.28 | -0.23 | $600.64 M | $622.10 M |
08/01/2024 | Q2 2024 | $1.05 | $0.64 | -0.41 | $545.98 M | $590.20 M |
05/01/2024 | Q1 2024 | $1.01 | $0.43 | -0.58 | $515.30 M | |
02/09/2024 | Q4 2023 | $1.50 | $515.20 M | |||
10/31/2023 | Q3 2023 | $0.97 | $0.85 | -0.12 | $479.09 M | $498.80 M |
08/01/2023 | Q2 2023 | $0.78 | $0.98 | 0.2 | $447.34 M | $452.70 M |
05/03/2023 | Q1 2023 | $0.26 | -$0.79 | -1.05 | $420.40 M | |
02/09/2023 | Q4 2022 | $0.92 | $412.00 M | |||
11/01/2022 | Q3 2022 | $0.79 | $0.72 | -0.07 | $377.00 M | $387.90 M |
08/04/2022 | Q2 2022 | $0.56 | -$0.18 | -0.74 | $342.33 M | $378.20 M |
05/04/2022 | Q1 2022 | $0.35 | $0.15 | -0.2 | $310.60 M | |
02/11/2022 | Q4 2021 | $0.61 | -$0.08 | -0.69 | $312.00 M | |
11/01/2021 | Q3 2021 | $0.51 | $0.24 | -0.27 | $297.83 M | $296.00 M |
08/03/2021 | Q2 2021 | $0.48 | $0.45 | -0.03 | $273.19 M | $288.90 M |
05/05/2021 | Q1 2021 | $0.51 | $0.34 | -0.17 | $236.60 M | |
02/05/2021 | Q4 2020 | $3.72 | $247.90 M | |||
11/09/2020 | Q3 2020 | $0.11 | -$0.62 | -0.73 | $282.70 M | $258.50 M |
08/03/2020 | Q2 2020 | $0.73 | $0.86 | 0.13 | $261.31 M | $302.40 M |
05/06/2020 | Q1 2020 | $0.56 | $0.40 | -0.16 | $237.10 M | |
02/06/2020 | Q4 2019 | $0.37 | $244.10 M |
Neurocrine Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based off last year's report dates.
The conference call for Neurocrine Biosciences, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Neurocrine Biosciences, Inc.'s latest earnings report can be read online.
Neurocrine Biosciences, Inc. (:NBIX) has a recorded annual revenue of $1.89 B.
Neurocrine Biosciences, Inc. (:NBIX) has a recorded net income of $1.89 B. Neurocrine Biosciences, Inc. has generated $2.56 earnings per share over the last four quarters.
Neurocrine Biosciences, Inc. (:NBIX) has a price-to-earnings ratio of 35.48 and price/earnings-to-growth ratio is 2.82.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED